Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FAPON

Fapon is a global IVD raw materials & one-stop solutions company offering 700+ reagent raw materials for the applicat... read more Featured Products: More products

Download Mobile App




Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026

By LabMedica International staff writers
Posted on 16 Nov 2026

Fapon showcased its AI-engineered enzymes, reverse transcription technologies, and nucleic acid library preparation solutions at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, held November 10–14 in Seattle, Washington. More...

The company highlighted technologies for quantitative PCR (qPCR), reverse transcription PCR (RT-qPCR), and next-generation sequencing (NGS), focusing on enzyme performance and integrated molecular testing workflows.

Among the featured products was ProPrime II Taq DNA Polymerase, a second-generation antibody hot-start enzyme designed for rapid and multiplex PCR applications. The polymerase achieves complete antibody release within 10 seconds of heat activation and supports quadruplex qPCR in under 20 minutes. Evaluations demonstrated amplification in samples containing 5% whole blood and nine common PCR inhibitors, including hemoglobin and EDTA.

Fapon also presented MeloScript III WS Reverse Transcriptase, a third-generation hot-start enzyme developed for one-step RT-qPCR applications. The enzyme demonstrated approximately 64% blocking efficiency after one hour at 37°C and maintained reverse transcription performance following 10 minutes at temperatures between 52°C and 64°C. Its glycerol-free, lyophilization-ready formulation supports applications in near-patient molecular testing.

The company's reverse transcription portfolio also includes PreciAmp HS RT for reverse transcription loop-mediated isothermal amplification (RT-LAMP) and VeloScript I for short- and long-read NGS workflows. VeloScript I supports RNA inputs ranging from 10 pg to 10 µg and synthesizes full-length complementary DNA (cDNA) up to 15 kb at 55°C. The enzyme is designed for applications involving single-cell analysis and limited RNA samples.

For downstream sequencing, Fapon highlighted its RNA library preparation solutions, including the NK081 Poly(A) mRNA Magnetic Isolation Module. The module removes at least 95% of ribosomal RNA in under 40 minutes, while its stranded and non-stranded RNA library preparation kits support inputs from 1 ng to 1 µg. The kits are compatible with sequencing platforms from Illumina, MGI, GeneMind, and Salus.

The company's DNA library preparation portfolio includes the NextGen Universal FS DNA Library Prep Kit, which uses enzymatic fragmentation and completes library preparation in under one hour. Together, these RNA and DNA solutions are designed to support molecular pathology workflows ranging from nucleic acid processing to sequencing library construction.

Fapon also hosted a technical workshop titled "Unlocking the Full Potential of Enzymes in Molecular Diagnostics." The session examined how AI-assisted enzyme engineering can improve performance across qPCR, RT-qPCR, NGS, and isothermal amplification. Presentations also addressed full-length transcriptomics and its application in resolving complex fusion genes and transcript isoforms.

Fapon's enzyme development approach combines AI-driven molecular design with high-throughput laboratory characterization to evaluate thermostability, sensitivity, specificity, amplification speed, and inhibitor resistance. The company also provides custom enzyme development, reagent formulations, and manufacturing services through bulk supply and OEM/ODM arrangements for in vitro diagnostic manufacturers.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.